Oligomerix Inc.
Targeting tau to treat Alzheimer’s disease
This article was originally published in Start Up
Executive Summary
Oligomerix Inc. is increasingly confident that small aggregates of the protein tau are a key culprit in the progression of Alzheimer’s disease. It aims to inhibit tau oligomer formation or self-association, the initial steps in aggregation of the protein, and thereby interrupt the disease process at a relatively early juncture.